title: Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure.
abstract: BACKGROUND
  Plasma N-terminal proatrial natriuretic factor (N-terminal proANF) has been shown to reflect intraatrial pressures in heart failure patients, and may be used as a biochemical parameter of atrial pressures. It is still unclear how treatment of heart failure influences the relationship between hemodynamic parameters and plasma levels of N-terminal proANF.
  
  
  RESULTS
  This double-blind, placebo-controlled study investigated whether 12 weeks of treatment with the angiotensin II receptor blocker losartan influenced N-terminal proANF plasma levels in 129 chronic heart failure patients. After 12 weeks of treatment, N-terminal proANF level was increased in patients given placebo by 344 +/- 1126 pmol/L, whereas in patients given 50 mg losartan, the levels had decreased by 251 +/- 886 pmol/L (P < .01 vs placebo). The change in N-terminal proANF correlated significantly with the corresponding change in pulmonary capillary wedge pressure (r = .53, P < .001).
  
  
  CONCLUSIONS
  The correlation between N-terminal proANF plasma levels and pulmonary capillary wedge pressure at baseline, as well as the correlation between the changes in these parameters during treatment, suggests that plasma N-terminal proANF may be used to monitor effects on left ventricular filling pressures in patients treated with losartan.
authors.affiliation: Institute for Surgical Research, National Hospital, University of Oslo, Norway.
authors.forename: R
authors.initials: R
authors.lastname: Klinge
authors.forename: A
authors.initials: A
authors.lastname: Polis
authors.forename: K
authors.initials: K
authors.lastname: Dickstein
authors.forename: C
authors.initials: C
authors.lastname: Hall
mesh_terms: D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001713:Biphenyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006439:Hemodynamics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D019808:Losartan; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000097:blood*; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D011498:Protein Precursors; D013777:Tetrazoles; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D019808:Losartan